Vilon
Status
No approved product. No FDA-approved labeling exists. Not approved in the United States; status in other countries, including Russia and neighbouring states, was not verified here.
What it is
A dipeptide studied in Russian work for immune and aging markers.
What published research measured
A synthetic dipeptide from the Khavinson programme, developed as a defined analogue of the thymus extract thymalin and proposed to carry its immunomodulatory activity in a standardized two-residue form. This substitution is the crux of how the category should be read: the clinical and mortality data belongs to the tissue extract, while the product usually sold is the synthetic derivative, and evidence does not automatically transfer from one to the other. Published work on the synthetic peptide is preclinical and observational, single-institute and largely Russian-language, and the sources cited in this entry show no ClinicalTrials.gov registration and no independent replication of the central claims. The programme's proposed mechanism — that a peptide this short enters the nucleus and regulates specific genes by binding promoter DNA — is not accepted in mainstream structural biology.
Source
Khavinson programme publications; this entry cites no independent replication
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.